ESG Report 2022

4.2.3 Improve Healthcare Standards The Group is committed to promoting the growth Association and the Annual Meeting of the of the pharmaceutical industry, as well as the Chinese Society of Clinical Pharmacy. During promotion of pharmaceutical academic and the year, the Group participated in 13 high-level medicinal information. During the year, the academic forums across the country with over Group actively participated in a multiple high- 1,000 attendees. In addition, the Group level pharmacetical academic forums, including continues to organise the "Double Excellence the Annual Meeting of the Diabetes Committee Campaign" - grassroots diabetes prevention and of the Chinese Research Hospital Association, ma n a g eme n t t r a i n i n g s e r i e s , a c t i v e l y the Annual Meeting of the Endocrinology and contributing to the improvement of the rational Metabolism Committee of the Physicians clinical use of diabetes drugs. Cooperation agency: Diabetes Medical Committee of Chinese Research Hospital Association, Liantang Zhongkang (Beijing) Medical Information Consulting Co., Ltd. The "Double Excellence Action" – Diabetes This year, the "Double Excellence Action" was Prevention and Management Training for launched in five cities across China, providing Grassroots Series is a nationwide public guidance and education to 11,000 healthcare service training programme organised by the professionals through online and offline Diabetes Committee of the Chinese Research formats. The Group will continue to promote the Hospital Association and exclusively supported prevention and management of diabetes at the by the Group. The programme aims to cultivate grassroots level, build a professional academic doctors with "double-excellent" capabilities, brand, establish a communication platform for which include excellent diabetes diagnosis and medical practitioners and contribute to the treatment, as well as excellent diabetes protection of public health and safety. knowledge dissemination. Since its launch, the programme has been held for 4 consecutive years, with over 50 sessions covering more than 20 provinces and cities across China and over 30,000 grassroots care practitioners participating. This programme has a positive impact on enhancing doctors' ability in diabetes diagnosis and management, standardizing the standard of grassroots care doctors, and improving the quality of care services for grassroots. “ Double Excellence Action” - Diabetes Prevention and Management Training for Grassroots Series Adhering to the tenet of "To Make Life More are one of the Group's major product categories, Valuable", the Group places a great importance to the Group strictly complies with the "Administrative public health and supports the provisions of the Measures for the Clinical Application of “Doha Declaration on the Agreement on Trade- Antibacterial Drugs" promulgated by the Related Aspects of Intellectual Property Rights go v e r nmen t and t he " C l a s s i f i c a t i on and Management Catalogue of Clinical Application of (TRIPS ） and Public Health” on protecting public Antibacterial Drugs" issued in various regions, and health and granting compulsory licences for actively cooperates to control and reduce the relevant patents in emergency situations. In occurrence of antibiotics abuse. To address the addition, as a generic drug manufacturer, the Group issue of antibiotic resistance, the Group is supports fair competition for generic drugs. developing a Class 1 new drug LB2311 suitable for drug-resistant bacterial infections. As of the end of The Group actively promotes the rational use of this report period, the project is in the preclinical antibiotics as the misuse of antibiotics leads to research stage. increased antibiotic resistance, which inevitably poses threat to public health. As antibacterial drugs 18 Environmental, Social and Governance Report 2022 The United Laboratories International Holdings Limited